Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ND095
- Development stage
- Preclinical
- Lead developer
- Numab Therapeutics
- Modality
- Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
ND095 is a multispecific antibody candidate being developed by Numab Therapeutics for the treatment of central nervous system (CNS) disorders. The molecule is engineered using Numab's proprietary MATCH™ and λ-Cap™ platforms, which enable the development of stable, multi-target biologics. ND095 is designed to simultaneously neutralize multiple complementary disease-inducing pathways, aiming to address CNS indications with a high global disease burden. While the specific molecular targets and the exact clinical development stage have not been publicly disclosed, the program is positioned as a potential first-in-class therapeutic within Numab's internal pipeline.
Beyond the preview
Go deeper on ND095.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ND095.